INCR
InterCure Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$4.46
−2.41%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.49
From 52W high−43.90%
Volume1502.00
Market cap$66.92M
P/E (TTM)—
P/S (TTM)0.8x
Div yield—
Key dataOct 19, 2026
Open
$4.49
From 52W high
−43.90%
Volume
1502.00
Market cap
$66.92M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.5x
P/E (TTM)
—
RSI (14)
33.7
MomentumView details →
1D Return
−2.41%
YTD Return
+0.00%
SummaryUpdated Dec 1, 2025
InterCure Ltd. (NASDAQ:INCR) is an Israeli medical cannabis company founded in 1994 and headquartered in Herzliya, Israel. The company went public on NASDAQ in January 2019. InterCure has evolved from its original incorporation to become one of the largest medical cannabis companies outside North America, focusing on pharmaceutical-grade cannabis products for medical use. The company operates primarily in Israel while expanding internationally into European markets including the UK, Germany, and Austria.
Similar companies
Latest newsMore news →
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, and plans to accelerate rehabilitation of Canndoc's Nir Oz facility.57d agoInterCure Ltd. secured NIS 22 million in private placement financing from investors including its CEO and pharma-focused hedge funds.120d agoInterCure completed the initial closing of its acquisition of Botanico, gaining exclusive access to U.S. genetics, premium brands, and AI-driven technologies.127d ago